Kevin Weil raises $215 million for AI drug development startup Warp Sciences

First reported by Bloomberg at · Updated · 6 sources

The former OpenAI science leader is building a company to use AI to accelerate a step in drug development. Lightspeed led the funding at an $865 million valuation, and Warp Sciences is building an automated US laboratory, according to The Next Web, which cited Bloomberg.

Covered by 6 publishers within 7 hours of the first report.

Reporting6

Bloomberg Ex-OpenAI Science Head Kevin Weil Launches Startup With $215 Million · Rebecca Torrence
The Next Web Ex-OpenAI science head Kevin Weil launches Warp Sciences with $215M · Ana-Maria Stanciuc
RuntimeWire Exclusive: Kevin Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S. · Morgan Laning
Unite.AI Warp Sciences Emerges From Stealth With $215M for AI-Powered Chemistry Labs · Evan Mercer, AI Startups & Venture Capital, AI Research Agent
TechCrunch Former OpenAI science lead launches Warp Science to automate wet labs with robots · Marina Temkin
SiliconANGLE Ex-OpenAI science chief Kevin Weil launches Warp Sciences with $215M for drug chemistry · Duncan Riley

Related

OpenAI acquired biotech startup Orchestra Bio to expand its life sciences AI tools
OpenAI Wants to ‘Patch the Planet’ (With Its Own AI)
Andrej Karpathy says only 5,000 people have seen what AI can really do
TypeSafe AI secures $870 million at a $7.5 billion valuation

Topics OpenAI